Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3133340 | 1.00 | SLC6A2 (0.70) | SLC6A2SLC6A4MAPK8MAPK9HTR7 | |
| SCHEMBL3138734 | 0.82 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL3142436 | 0.82 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL3138406 | 0.81 | SLC6A2 (0.71) | SLC6A2SLC6A4 | |
| SCHEMBL3147064 | 0.81 | SLC6A2 (0.71) | SLC6A2SLC6A4 | |
| SCHEMBL3137003 | 0.81 | SLC6A2 (0.71) | SLC6A2SLC6A4 | |
| SCHEMBL3137238 | 0.79 | SLC6A2 (0.72) | SLC6A2SLC6A4PGR | |
| SCHEMBL3137252 | 0.78 | SLC6A2 (0.73) | SLC6A2SLC6A4 | |
| SCHEMBL3138374 | 0.77 | SLC6A2 (0.72) | SLC6A2SLC6A4 | |
| SCHEMBL3151314 | 0.77 | SLC6A2 (0.72) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687529-B2 | Substituted propylamine derivatives and methods of their use | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | TPH1, HTR1A, HTR5A | SLC6A2 9/4885SLC6A4 4/4885MAPK8 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.